摘要
目的:研究增殖诱导配体(APRIL)mRNA及蛋白的表达与B细胞非霍奇金淋巴瘤(B-NHL)患者临床分期、肿瘤负荷及疗效的关系。方法:采用实时荧光定量聚合酶链反应(RFQ-PCR)和酶联免疫吸附试验(ELISA)方法,检测各期B-NHL患者化疗前后外周血单个核细胞和血浆中APRIL mRNA及蛋白含量的变化。结果:化疗前,B-NHLⅢ期及Ⅳ期患者APRIL mRNA及蛋白表达明显高于Ⅰ/Ⅱ期(P<0.05),但Ⅲ期与Ⅳ期之间差异无统计学意义(P>0.05);化疗后,Ⅲ期与Ⅰ/Ⅱ期及Ⅳ期差异无统计学意义(P>0.05),但Ⅳ期明显高于Ⅰ/Ⅱ期(P<0.05)。化疗后B-NHL患者进展(PD)组APRIL mRNA及蛋白表达显著高于完全缓解(CR)及部分缓解(PR)组,与无变化(NC)组差异无统计学意义(P>0.05),且CR、PR及NC组间差异无统计学意义(P>0.05)。结论:APRIL与B-NHL的分期、肿瘤负荷量及疗效密切有关,且可能成为有效治疗B-NHL的新靶点。
Objective：Study on the relationship between the level of a proliferation-inducing ligand（APRIL）mRNA and protein in patients with B cells non-Hodgkin lymphoma（B-NHL）and its clinical stage,tumor burden and efficacy.Method：Real-time fluorescence quantitative polymerase chain reaction（RFQ-PCR）and enzyme-linked immunosorbent assay（ELISA）were used to determine the level of APRIL mRNA and protein in peripheral blood mononuclear cells and plasma in patients with B-NHL before and after chemotherapy.Result：Before chemotherapy,the expression level of APRIL mRNA and protein in patients with Ⅲ and Ⅳ stage of B-NHL were significantly higher than that of Ⅰ/Ⅱ stage（P0.05,respectively）,but there were no significant difference between Ⅲ stage and Ⅳ stage（P0.05）.After chemotherapy,the expression level of patients with Ⅲ stage of B-NHL were not significantly different from those of Ⅳ and Ⅰ/Ⅱ stage（P0.05,respectively）,but there were significant difference between Ⅰ/Ⅱ stage and Ⅳ stage（P0.05）.In the treated-patients with B-NHL,the expression levels of APRIL mRNA and protein in PD group were also significantly higher than those of CR and PR（P0.05,respectively）,but no significantly difference between CR,PR,and NC groups（P0.05）.Conclusion：APRIL may be intimately relative to stage,burden and efficacy.It could be established as a target molecule to treat B-NHL efficiently.
出处
《临床血液学杂志》
CAS
2012年第5期576-579,共4页
Journal of Clinical Hematology
关键词
淋巴瘤
非霍奇金
增殖诱导配体
实时荧光定量聚合酶链反应
酶联免疫吸附试验
Non-Hodgkin lymphoma
proliferation-inducing ligand
real-time fluorescence quantitative polymerase chain reaction
enzyme-linked immunosorbent assay
